St. Jude Care & Treatment

Menu

Close

Recruiting

SJALL23H: Treatment of High-Risk Leukemia/Lymphoma

About this study 

B-cell acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LLy, a type of Non-Hodgkin lymphoma) are usually treated with a mix of cancer-fighting drugs called chemotherapy. Chemotherapy kills the leukemia cells that are in the blood and the bone marrow. Four to 7 chemotherapy drugs are usually used during the first part of treatment.

This study will see if a new mix, including 2 new chemotherapy drugs, is better at getting rid of leukemia and lymphoma in the blood and the bone marrow than the usual 4 to 7 drugs. The 2 new medicines are called inotuzumab and blinatumomab. These drugs have been approved by the U.S. Food and Drug Administration (FDA) to treat children whose leukemia has come back after other treatment. Blinatumomab has also been approved for use in children with new diagnoses but not for use during induction. Inotuzumab has not been used for children with new diagnoses.

The goal of this treatment is to compare the effects (good and/or bad) of adding inotuzumab and blinatumomab to standard chemotherapy for these diseases.  We also hope to prevent the disease from coming back.

Eligibility overview 

  • Age 1–18 years
  • Enrolled in INITIALL clinical trial
  • No chemotherapy unless given during or allowed by INITIALL
  • No active, uncontrolled infection

Request a referralLearn about clinical research

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Overview

Full title:

SJALL23H: Combination Antigen-Directed Induction Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma 

Study goal:

To compare the effects of adding inotuzumab and blinatumomab to standard chemotherapy during treatment for newly diagnosed ALL and LLy; to learn whether the length of time that inotuzumab stays in the body affects treatment success or side effects; to learn more about the biological and genetic or genomic traits that predict treatment success and toxicity

Diagnosis:

B-cell acute lymphoblastic leukemia, lymphoblastic leukemia, lymphoblastic lymphoma (Non-Hodgkin lymphoma)

Age:

1-18 years

Clinical trials categories:

Childhood Cancer Lymphoma Leukemia Non-Hodgkin Lymphoma

For physicians and researchers

Patients accepted to St. Jude must be referred by a physician or other qualified medical professional. Learn how St. Jude can partner with you to care for your patient.

 

Learn more